Cargando…

Leishmania Vesicle-Depleted Exoproteome: What, Why, and How?

Leishmaniasis, a vector-borne parasitic protozoan disease, is among the most important neglected tropical diseases. In the absence of vaccines, disease management is challenging. The available chemotherapy is suboptimal, and there are growing concerns about the emergence of drug resistance. Thus, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Esteves, Sofia, Costa, Inês, Luelmo, Sara, Santarém, Nuno, Cordeiro-da-Silva, Anabela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781507/
https://www.ncbi.nlm.nih.gov/pubmed/36557688
http://dx.doi.org/10.3390/microorganisms10122435
_version_ 1784857091185311744
author Esteves, Sofia
Costa, Inês
Luelmo, Sara
Santarém, Nuno
Cordeiro-da-Silva, Anabela
author_facet Esteves, Sofia
Costa, Inês
Luelmo, Sara
Santarém, Nuno
Cordeiro-da-Silva, Anabela
author_sort Esteves, Sofia
collection PubMed
description Leishmaniasis, a vector-borne parasitic protozoan disease, is among the most important neglected tropical diseases. In the absence of vaccines, disease management is challenging. The available chemotherapy is suboptimal, and there are growing concerns about the emergence of drug resistance. Thus, a better understanding of parasite biology is essential to generate new strategies for disease control. In this context, in vitro parasite exoproteome characterization enabled the identification of proteins involved in parasite survival, pathogenesis, and other biologically relevant processes. After 2005, with the availability of genomic information, these studies became increasingly feasible and revealed the true complexity of the parasite exoproteome. After the discovery of Leishmania extracellular vesicles (EVs), most exoproteome studies shifted to the characterization of EVs. The non-EV portion of the exoproteome, named the vesicle-depleted exoproteome (VDE), has been mostly ignored even if it accounts for a significant portion of the total exoproteome proteins. Herein, we summarize the importance of total exoproteome studies followed by a special emphasis on the available information and the biological relevance of the VDE. Finally, we report on how VDE can be studied and disclose how it might contribute to providing biologically relevant targets for diagnosis, drug, and vaccine development.
format Online
Article
Text
id pubmed-9781507
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97815072022-12-24 Leishmania Vesicle-Depleted Exoproteome: What, Why, and How? Esteves, Sofia Costa, Inês Luelmo, Sara Santarém, Nuno Cordeiro-da-Silva, Anabela Microorganisms Review Leishmaniasis, a vector-borne parasitic protozoan disease, is among the most important neglected tropical diseases. In the absence of vaccines, disease management is challenging. The available chemotherapy is suboptimal, and there are growing concerns about the emergence of drug resistance. Thus, a better understanding of parasite biology is essential to generate new strategies for disease control. In this context, in vitro parasite exoproteome characterization enabled the identification of proteins involved in parasite survival, pathogenesis, and other biologically relevant processes. After 2005, with the availability of genomic information, these studies became increasingly feasible and revealed the true complexity of the parasite exoproteome. After the discovery of Leishmania extracellular vesicles (EVs), most exoproteome studies shifted to the characterization of EVs. The non-EV portion of the exoproteome, named the vesicle-depleted exoproteome (VDE), has been mostly ignored even if it accounts for a significant portion of the total exoproteome proteins. Herein, we summarize the importance of total exoproteome studies followed by a special emphasis on the available information and the biological relevance of the VDE. Finally, we report on how VDE can be studied and disclose how it might contribute to providing biologically relevant targets for diagnosis, drug, and vaccine development. MDPI 2022-12-08 /pmc/articles/PMC9781507/ /pubmed/36557688 http://dx.doi.org/10.3390/microorganisms10122435 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Esteves, Sofia
Costa, Inês
Luelmo, Sara
Santarém, Nuno
Cordeiro-da-Silva, Anabela
Leishmania Vesicle-Depleted Exoproteome: What, Why, and How?
title Leishmania Vesicle-Depleted Exoproteome: What, Why, and How?
title_full Leishmania Vesicle-Depleted Exoproteome: What, Why, and How?
title_fullStr Leishmania Vesicle-Depleted Exoproteome: What, Why, and How?
title_full_unstemmed Leishmania Vesicle-Depleted Exoproteome: What, Why, and How?
title_short Leishmania Vesicle-Depleted Exoproteome: What, Why, and How?
title_sort leishmania vesicle-depleted exoproteome: what, why, and how?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781507/
https://www.ncbi.nlm.nih.gov/pubmed/36557688
http://dx.doi.org/10.3390/microorganisms10122435
work_keys_str_mv AT estevessofia leishmaniavesicledepletedexoproteomewhatwhyandhow
AT costaines leishmaniavesicledepletedexoproteomewhatwhyandhow
AT luelmosara leishmaniavesicledepletedexoproteomewhatwhyandhow
AT santaremnuno leishmaniavesicledepletedexoproteomewhatwhyandhow
AT cordeirodasilvaanabela leishmaniavesicledepletedexoproteomewhatwhyandhow